PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.56%
Net income growth under 50% of VET's 45.86%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-3.78%
Negative yoy D&A while VET is 32.04%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-355.68%
Negative yoy deferred tax while VET stands at 132.63%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
10.87%
SBC growth while VET is negative at -12.50%. John Neff would see competitor possibly controlling share issuance more tightly.
-116.13%
Negative yoy working capital usage while VET is 556.04%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-88.00%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
141.64%
Inventory growth of 141.64% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
80.58%
AP growth of 80.58% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-116.13%
Negative yoy usage while VET is 556.04%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-4.71%
Both negative yoy, with VET at -9237.35%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-9.04%
Negative yoy CFO while VET is 10.63%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
29.94%
CapEx growth well above VET's 7.99%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-219.25%
Both yoy lines negative, with VET at -63.14%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.24%
Both yoy lines negative, with VET at -73.54%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-123.86%
We reduce yoy invests while VET stands at 0.13%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
99.81%
We repay more while VET is negative at -62.38%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
42.15%
Buyback growth below 50% of VET's 100.00%. Michael Burry suspects fewer capital returns to shareholders vs. competitor, unless expansions hold higher ROI.